New strategies to reduce nephrotoxicity

Transplantation

Volumn 72, Issue 12 SUPPL., 2001, Pages

  Kreis, H ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN; CYCLOSPORIN A; INTERLEUKIN 2 RECEPTOR ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PREDNISONE; RAPAMYCIN; TACROLIMUS;

CLINICAL TRIAL; CONFERENCE PAPER; DRUG MECHANISM; DRUG POTENTIATION; HUMAN; HYPERTENSION; HYPERURICEMIA; HYPOKALEMIA; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; SKIN CARCINOMA; TACHYCARDIA; THROMBOCYTOPENIA;

EID: 0035677594     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (61)

1. Clinical pharmacology of immunosuppressive drugs: Year 2000 - Time for alternatives
2. Renal transplantation, past, present and future
3. Neoral absorption profiling: An evolution in effectiveness
4. FK506 for liver, kidney and pancreas transplantation
5. Tacrolimus. An update of its pharmacology and clinical efficacy in the management of organ transplantation
6. Tacrolimus. A review of its pharmacology, and therapeutic potential in hepatic and renal transplantation
7. Risk for posttransplant diabetes mellitus with current immunosuppressive medications
8. Racial differences in renal transplantation after immunosuppression with tacrolimus versus cyclsoporine
9. Patient, graft, and functional survuval rates: An overview
10. Cyclosporine immunosuppression
11. Improved graft survival after renal transplantation in the United States, 1988 to 1996
12. Long-term benefits and risks of cyclosporin A (Sandimmune) - An analysis at 10 years
13. Factors contributing to long-term kidney graft survival in Eurotransplant
14. Cyclosporin A in patients receiving renal allografts from cadaver donors
15. Is nonnephrotoxic immunosuppression a possibility?
16. Nephrotoxicity of immunosuppressive drugs: Long-term consequences and challenges for the future
17. Nonimmunologic renal allograft injury and delayed graft function: Clinical strategies for prevention and treatment
18. Which calcineurin inhibitor is preferred in renal transplantation: Tacrolimus or cyclosporine
19. The side-effects of ciclosporine-A and tacrolimus
20. Mechanisms of nephrotoxicity
21. Tacrolimus induces increased expression of transforming growth factor-β1 in mammalian lymphoid as well as nonlymphoid cells
22. Mechanism of fibrosis in experimental tacrolimus nephrotoxicity
23. Immunoregulatory and fibrogenic activities of cyclosporine: A unifying hypothesis based on transforming growth factor-β expression
24. Role of transforming growth factor-β1 in experimental chronic cyclosporine nephropathy
25. Transforming growth factor-β levels in human allograft chronic fibrosis correlate with rate of decline in renal function
26. The clinical impact of nephrotoxicity in renal transplantation
27. Chronic renal failure following liver transplantation: A retrospective analysis
28. Cyclosporine-associated chronic nephropathy
29. Histopathology of chronic renal allograft dysfunction
30. Histopathology of calcineurin inhibitor-induced nephrotoxicity
31. The effect of triple therapy on cyclosporine nephrotoxicity and hypertension in renal transplantation
32. Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: Randomised comparison of two cyclosporine regimens
33. High- and low-dose regimens of cyclosporin in renal transplantation: Immunosuppressive efficacy and side effects
34. Low exposure to cylosporine is a risk factor for the occurrence of chronic rejection after kidney transplantation
35. Causes of late renal allograft loss: Chronic allograft dysfunction, death, and other factors
36. Comparison of three immunosuppresive regimens in cadaver renal transplantation: Long-term cyclosporine, short-term cyclosporine followed by azathioprine and prednisolone, and azathioprine and prednisolone without cyclosporine
37. Cyclosporin treatment with conversion after three months versus conventional immunosuppression in renal allograft recipients
38. Beneficial effects of conversion from cyclosporine to azathioprine after kidney transplantation
39. A meta-analysis of immunosuppression withdrawal trials in renal transplantation
40. Newer immunosuppressive drugs: A review
41. Prevention of transplant rejection. Current treatment guidelines and future developments
42. Cyclosporine withdrawal in stable renal transplant recipients after azathioprine-mycophenolate mofetil conversion
43. Avoidance of cyclosporine in renal transplantation: Effects of daclizumab, mycophenolate mofetil, and steroids
44. Low-dose cyclosporine and mycophenolate mofetil in renal allograft recipients with suboptimal renal function
45. Immunophilins: Beyond immunosuppression
46. Molecular mechanisms of the immunosuppressive action of cyclosporin A
47. Mammalian target of rapamycin: Immunosuppressive drugs uncover a novel pathway of cytokine receptor signaling
48. Sirolimus (rapamycin) potentiates cyclosporine in prevention of acute lung rejection
49. Synergistic effect of rapamycin and cyclosporine in prevention of acute kidney allograft rejection in the mouse
50. Rapamycin and cyclosporine synergistically prolong heart and kidney allograft survival
51. Effect of tacrolimus (FK506) and sirolimus (rapamycin) mono- and combination therapy in prolongation of renal allograft survival in the monkey
52. Tacrolimus (FK506) and sirolimus (rapamycin) in combination are not antagonistic but produce extended graft survival in cardiac transplantation in the rat
53. Synergistic effects of mycophenolate mofetil and sirolimus in prevention of acute heart, pancreas, and kidney allograft rejection and in reversal of ongoing heart allograft rejection in the rat
54. Vascular and cellular mechanisms of chronic renal allograft dysfunction
55. Sirolimus (rapamycin) halts and reverses progression of allograft vascular disease in non-human primates
56. Acute effects of rapamycin on glomerular dynamics: A micropuncture study in the rat
57. Comparison of acute rapamycin nephrotoxicity with cyclosporine and FK506
58. Potential therapeutic interventions to avoid or treat chronic allograft dysfunction
59. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients
60. Effect of cyclosporine on mycophenolic acid trough levels in kidney transplant recipients
61. Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure